RPS6KB2 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, all mice that received CML-KLS+ cells from vehicle-treated CML-affected animals developed BCR-ABL1+ disease and were dead before 80 days, demonstrating that the untreated CML-KLS+ cells had retained their CML-initiating ability.